All In Biotech

Drug Trial Radar · NCT07140328

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 24, 2025

Primary completion

Jul 10, 2025

Study completion Aug 2026

Sponsor

Sponsor type
Industry
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.

Conditions

  • Chronic Obstructive Lung Disease (COLD)

Interventions

  • HSK39004 Dry Powder Inhaler -0.75mg BIDDrug

    HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day; And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ;

  • HSK39004 Dry Powder Inhaler -1.5mg BIDDrug

    HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day; And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ;

  • HSK39004 Inhalation Suspension -3mg BIDDrug

    HSK39004 Inhalation Suspension: Inhale through the mouth, 3mg each time, twice a day; And HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ;

  • HSK39004 PlaceboDrug

    HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ; And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. The ΔFEV1 AUC0-12h after the 4th week administration (the area under the curve representing the change in FEV1 from baseline to 12 hours after administration)Time frame: Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Provincial People's Hospital

    Nanchang, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.